Although the expression of PD-L1 within tumor cells is known to predict the efficacy of PD-1 blockade in patients with NSCLC, two exploratory investigations indicated that PD-L1 has the potential to precisely predict PD-1 blockade in TC [9,10]. Here, CD274 is linked to neoplasm.